Key challenges in the use & development of digital endpoints from a health technology assessment (HTA) perspective BREAKING
NEWS
Why Mobilise-D matters – now more than ever! LATEST
VIDEO
More Videos
IEEE Transactions on Biomedical Engineering A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different
Disability Levels
Angelini L., Buckley, E. Bonci T., Radford A., Sharrack B., Paling D., Nair K., Mazzà C. Other publications LATEST
PUBLICATION
SOCIAL MEDIA Eleanor BREAKING
NEWS
Why Mobilise-D matters – now more than ever! LATEST
VIDEO
More Videos
IEEE Transactions on Biomedical Engineering A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different
Disability Levels
Angelini L., Buckley, E. Bonci T., Radford A., Sharrack B., Paling D., Nair K., Mazzà C. Other publications LATEST
PUBLICATION
SOCIAL MEDIA It’s a kind of magic: the validation study has been Mobilise-D against all odds BREAKING
NEWS
Why Mobilise-D matters – now more than ever! LATEST
VIDEO
More Videos
IEEE Transactions on Biomedical Engineering A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different
Disability Levels
Angelini L., Buckley, E. Bonci T., Radford A., Sharrack B., Paling D., Nair K., Mazzà C. Other publications LATEST
PUBLICATION
SOCIAL MEDIA New publication: A roadmap to inform development, validation and approval of digital mobility outcomes: the Mobilise-D approach BREAKING
NEWS
Why Mobilise-D matters – now more than ever! LATEST
VIDEO
More Videos
IEEE Transactions on Biomedical Engineering A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different
Disability Levels
Angelini L., Buckley, E. Bonci T., Radford A., Sharrack B., Paling D., Nair K., Mazzà C. Other publications LATEST
PUBLICATION
SOCIAL MEDIA – I felt Mobilise-D! BREAKING
NEWS
Why Mobilise-D matters – now more than ever! LATEST
VIDEO
More Videos
IEEE Transactions on Biomedical Engineering A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different
Disability Levels
Angelini L., Buckley, E. Bonci T., Radford A., Sharrack B., Paling D., Nair K., Mazzà C. Other publications LATEST
PUBLICATION
SOCIAL MEDIA MDS Virtual Congress 2020 BREAKING
NEWS
Why Mobilise-D matters – now more than ever! LATEST
VIDEO
More Videos
IEEE Transactions on Biomedical Engineering A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different
Disability Levels
Angelini L., Buckley, E. Bonci T., Radford A., Sharrack B., Paling D., Nair K., Mazzà C. Other publications LATEST
PUBLICATION
SOCIAL MEDIA

Connecting digital mobility assessment to clinical outcomes
for regulatory and clinical endorsement

What?

What?

Mobilise-D is a 5-year, IMI-funded project that will produce validated and accepted digital mobility outcomes to monitor daily life gait of people with different mobility problems, with the goal to improve follow-up and personalized care.

How?

How?

Mobilise-D will perform a technical and clinical validation of a sensor-algorithm pair in different patient groups. We maintain close dialogue with the European Medicines Agency (EMA) to facilitate the process of regulatory approval.

Who?

Who?

The Mobilise-D consortium consists of 34 partners from Europe and the USA. Over 200 professionals with technical, clinical, and regulatory expertise will work together to bring digital mobility outcomes to the clinic.                                                                  

Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with greater mortality, morbidity, cognitive decline, dementia, and fall risk. As the population ages, the number of people experiencing mobility challenges is expected to rise. However, accurately assessing people’s mobility, especially in the real daily life world, is far from easy.

Mobilise-D will develop a comprehensive system to monitor and evaluate people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care.

Patient Groups

Mobilise-D will focus on five different patient groups that together represent respiratory problems (chronic obstructive pulmonary disease – COPD), neurodegenerative conditions (Parkinson’s disease – PD), neuroinflammatory problems (multiple sclerosis – MS), osteoporosis and sarcopenia (hip fracture recovery/proximal femoral fracture – PFF), and cardiac pathology (congestive heart failure – CHF).

These patient groups cover a range of walking speed, mobility challenges, and potential events that we care about, such as improving versus worsening of function, falls, hospitalisation, nursing home admission, and death. Furthermore, these patient groups will be followed at 12 different sites across Europe, ensuring a good geographical representation and covering a diverse representation of health care organisation, such as in- versus outpatient care, as well as public versus private health services.

Read More

Twitter Feed


🆕📄 #DigitalEndpoints offer a great potential to be considered in the #HealthTechnologyAssessment framework. There is so far no institutional way in. Read some perspectives on several important issues here⤵️

https://t.co/KK7u73Zs6e https://t.co/IxhzVJadNx
Mobilise_D photo

🔎📖✅We have created a new #MobiliseD Community on @ZENODO_ORG. The goal is to provide #OpenAccess to all our publications!

🔗 https://t.co/0IRHhMghs4

All our publications can be found on our website and @OpenAIRE_eu:
➡️ https://t.co/nE5aKplodv
➡️ https://t.co/zELQGdiVQP

Latest News

Key challenges in the use & development of digital endpoints from a health technology assessment (HTA) perspective

Digital endpoints offer a great potential to be considered in the HTA framework. So far, however, there is no institutional way in.  On February 15, 2021, IMI Neuronet hosted an online meeting of its working group on health technology assessment (HTA) and regulatory interactions, moderated by Diana O’Rourke from the National Institute for Health and Care Excellence (NICE). The discussions were based around the experiences of three different IMI projects that are…

Upcoming Events